Safety review

BPC-157 Side Effects: What Is Actually Known

Sellers describe BPC-157 as well tolerated with no reported side effects. That claim rests on an absence of data rather than a body of it, and the difference between those two things is the whole subject of this page.

  • OneRegistered human trials designed to measure BPC-157 adverse events
  • 2015The year that trial last filed a registry update. It has never posted results
  • NoneHuman clinical safety data found by a 2025 systematic review of the literature
  • S0The anti-doping category BPC-157 sits in: prohibited at all times

The short version

There is no established side-effect profile for BPC-157 in humans, because the studies that would establish one have not been completed and published. That is the honest answer, and it is a very different answer from “it is safe.”

What follows is what is actually documented: what regulators have said, what the single registered human safety trial was designed to find and what became of it, what the animal literature does and does not cover, and the risks that come from the product rather than from the peptide. Most pages answering this question present a tidy list of side effects. The evidence does not support one existing.

Why “no reported side effects” is not a safety finding

For a side effect to be reported, something has to be watching. Approved medicines build their safety profiles twice over: first in controlled trials that record every adverse event that occurs, and then through post-marketing surveillance that keeps collecting reports for as long as the drug is on the market. Both are obligations rather than courtesies, and both are what make a phrase like “the most common side effects are” mean anything at all.

BPC-157 sits outside both systems. It is not an approved drug, so no sponsor is obliged to collect adverse events from the people using it. It is not a dietary supplement, so it falls outside the reporting route that covers those. And it is generally sold labelled for research rather than for human use, which means that as far as the regulatory record is concerned, nobody is taking it at all.

Worth knowing

An absence of reports is exactly what you would expect from a substance nobody is formally monitoring — whether it causes harm or not. The absence carries no information in either direction.

The one human safety trial, and what became of it

In October 2015 a Croatian company, PharmaCotherapia, registered a Phase 1 study on ClinicalTrials.gov under the title “Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source.”

It was designed the way you would want it designed. Forty-two healthy volunteers. A placebo arm. And a primary outcome measure recorded on the registry as adverse events — any adverse event reported during the study, across a six-month window. This was, in other words, precisely the study that would answer the question this page is about.

Its registry record was last updated on 17 December 2015, when its status was active, not recruiting. The registry now carries its overall status as unknown. No results have been posted in the decade since.

Safety

The only registered study built to measure BPC-157 adverse events in humans has never reported them. That is the current state of human safety evidence for this compound, stated plainly.

The United States Anti-Doping Agency describes the same pattern in its own words: “there is a concerning lack of published human clinical trial data because studies appear to have been cancelled or stopped without any published conclusions.” A trial that starts and then goes quiet leaves nothing behind. Whatever it found, or failed to find, is not in the public record, and no one outside the sponsor can say which.

What the FDA has identified as the risks

The FDA has placed BPC-157 in Category 2 of its bulk drug substances review — substances it says may present significant safety risks. Its stated reasoning is worth reading in full rather than in summary, because it names specific mechanisms rather than gesturing at danger.

What the FDA says

“Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration.”

Two distinct concerns are packed into that. Immunogenicity is the possibility that the body mounts an immune response against the peptide itself, and the FDA ties that risk to the route by which it is given — the same substance can behave differently injected than taken by mouth. Impurities and active ingredient characterisation are a separate matter entirely: you cannot assess whether a substance is safe if you cannot establish what is in the container.

The closing sentence does the most work. The FDA is not saying it has looked and found harm. It is saying it has looked and found too little information to judge, which is a statement about the evidence rather than about the molecule. Our BPC-157 overview covers the Category 2 listing and the naming problem in more detail.

What the animal safety studies actually showed

A systematic review published in HSS Journal in 2025 searched PubMed, Cochrane and Embase from database inception to 3 June 2024. It identified 544 articles and, after screening, included 36 studies: 35 preclinical, and one clinical.

On safety its finding runs to two sentences, and both halves matter: “Preclinical safety studies showed no adverse effects across several organ systems. No clinical safety data were found.”

The animal safety record, in other words, looks clean, and we are not going to talk that down — it is a real finding. It is also the reason a compound gets taken into human trials rather than a substitute for having done so. Species differ in how they metabolise and respond to peptides, exposures in animal work rarely map onto human use, and the effects that most often stop a drug in humans, such as immune reactions, rare organ toxicity and interactions with other medicines, are among the least reliably predicted by animal models.

The same review reports that BPC-157 is metabolised in the liver, cleared by the kidneys, and has a plasma half-life of under 30 minutes. That is a pharmacokinetic sketch. It is not a safety profile, and it says nothing about what repeated exposure does over months.

BPC-157 side effects in women, and in men

These are among the most searched versions of the question, and they have the same answer as the general one, only more so. There is no sex-stratified human safety data for BPC-157, because there is no human safety data to stratify.

The Phase 1 study that would have enrolled healthy volunteers never reported. The single clinical study in the systematic review was a retrospective look at 12 patients who had received BPC-157 for chronic knee pain, and it was not designed to characterise adverse events at all, let alone break them down by sex.

Safety

We found no reproductive or developmental toxicology for BPC-157 in the public record. Where a compound has not been studied in pregnancy or breastfeeding, the accurate word is unstudied — not safe.

Any page offering a list of side effects specific to women, or specific to men, is not drawing on a source we have been able to find. If one exists we would genuinely like to see it, and we will update this page if it is produced.

The risks that come from the product, not the peptide

Everything above concerns BPC-157 as a molecule. What someone actually buys is a separate question, and it carries its own risks — risks that would exist even if the peptide itself turned out to be entirely benign.

  • Unregulated manufacturing. The systematic review names this directly in its conclusion: “Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.” Nothing in that sentence is about the peptide. All of it is about the supply.
  • What is actually in the vial. The FDA’s Category 2 entry flags peptide-related impurities and active ingredient characterisation as unresolved questions. These are not hypothetical worries about a rogue seller; they are the agency saying the composition of these products is not established.
  • Which BPC-157 you received. The name is a common name, not a United States Adopted Name, and more than one substance is sold under it. We cover this in the overview; it is the same class of problem we documented in compounded semaglutide, where the FDA reported salt forms it describes as different active ingredients from the approved drug.
  • The label on the box. The Department of Defense’s Operation Supplement Safety notes that products containing BPC-157 “might be labeled as ‘research chemicals’ and carry statements such as ‘Not for human consumption,’ ‘Research use only,’ or ‘For research purposes only.'” A product sold on those terms comes with no manufacturer standing behind its use in a person.

A consequence that is not medical at all

For anyone subject to drug testing, the most likely adverse consequence of BPC-157 has nothing to do with physiology. It was added to the World Anti-Doping Agency’s Prohibited List in 2022 under S0, the category covering substances with no approval from any government health authority for human therapeutic use.

S0 substances are prohibited at all times, in competition and out of it, so there is no off-season during which use is permitted. Presence or use is a rule violation regardless of timing and regardless of whether it improved anything. BPC-157 also appears on the Department of Defense prohibited list, and Operation Supplement Safety states flatly that “it is an unapproved drug and cannot be legally prescribed or sold over the counter.”

Worth knowing

The Phase 2 trial now recruiting excludes anyone enrolled in an anti-doping testing programme from taking part — a neat illustration of how far outside ordinary medicine this compound currently sits.

What this page will not tell you

  • How much to take, or how to reduce side effects by adjusting an amount. There is no approved labeling and no completed human trial establishing a dose, so every figure in circulation is someone’s inference.
  • How to reconstitute, inject or administer it, or which route is safer than another.
  • Which vendors are cleaner or better tested. We do not review grey-market suppliers.
  • Whether a symptom you are experiencing was caused by BPC-157. We do not employ clinicians and we have never met you. That question belongs to someone who can examine you.

Sources and method

  • The Phase 1 safety trial. NCT02637284 on ClinicalTrials.gov, sponsored by PharmaCotherapia. The enrollment figure, the primary outcome measure, the last-update date of 17 December 2015 and the current status of unknown are all read from that registry record.
  • The systematic review. Vasireddi and colleagues, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, HSS Journal, 2025. The study counts, the half-life, the safety sentences and the conclusion about unregulated manufacturing are quoted from its abstract.
  • The FDA position. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Quoted from the agency’s own page rather than from coverage of it.
  • Prohibited status. USADA on BPC-157 for the S0 classification and the observation about cancelled or stopped studies, and the Department of Defense’s Operation Supplement Safety for the labeling and legal-status quotations.
  • What we could not verify. We do not know why NCT02637284 stopped reporting, and we do not assert it was halted for a safety reason — only that it never published. We have read the systematic review’s abstract rather than its full text. We have not tested any product, and we have no way to know what any given vendor is shipping.
  • Method. Where this page says something is unknown, that reflects an absence we looked for and did not find, not an absence we assumed. Registry and regulatory records are read directly at source.

BPC-157 overview →   Regulatory tracker →   How we source and verify →

Registry and regulatory sources checked 30 August 2026. We recheck this page if NCT02637284 posts results or the FDA acts on BPC-157.